On first glance, Globus Medical (NYSE:GMED) looks like it could be one of the unicorns of the med-tech space - a legit growth story that the market hasn't already pushed up to a red-hot valuation. Globus has what seems to be a sustainable culture built around product innovation, and that steady stream of innovative products could be just the ticket for success in a price-constrained implant world. That said, valuation isn't quite the slam-dunk that value investors may hope to see.
As We Knew, Globus Did Well At The End Of 2012
Between the earlier release of Q4 revenue numbers and the results we've seen from other major spine companies like Johnson & Johnson (NYSE:JNJ), Medtronic...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|